The Journal of Immunology, Vol 138, Issue 3 788-794, Copyright © 1987 by American Association of Immunologists

ARTICLES

Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40)

JA Ledbetter, G Shu, M Gallagher and EA Clark

We recently described a 50,000 dalton polypeptide Bp50 (CDw40) that is expressed on human B cells and plays a role in regulating B cell proliferation. Here we additionally characterize the functional signal given by antibody binding to Bp50 on both normal and malignant B cells. A monoclonal anti-Bp50 antibody could augment the proliferation of B cells activated by anti-IgM, anti-CD20, or 12-O-tetradecanoyl phorbol- 13-acetate (TPA) stimulation, but was not co-stimulatory with B cell growth factor (BCGF), interleukin 1, or interleukin 2. The signal did not depend on the Fc portion of the antibody, because F(ab')2 fragments of anti-Bp50 were still functionally active. Both anti-Bp50 and a low m.w. BCGF preparation were similar in that both were co-stimulatory with the same agents and both anti-Bp50 and BCGF affected activated B cells but not resting B cells. However, a panel of B cell malignancies differed in their responsiveness to anti-Bp50 vs BCGF: some tumors proliferated in response to anti-Bp50 but not BCGF, whereas other tumors had the opposite pattern. Bp50 was found to have several properties in common with HLA class II molecules: both Bp50 and class II were expressed at lower levels on blood B cells than on tonsillar B cells; the expression of both Bp50 and class II was increased after activation of blood B cells with TPA or anti-IgM; and the expression of both Bp50 and class II was increased after activation of non T, non-B acute leukemias with BCGF. Thus class II and Bp50 expression may be under common regulatory control. The fact that BCGF modulated the expression of Bp50 on leukemic cells suggests that BCGF and Bp50- mediated signals may be coordinately regulated.

This article has been cited by other articles:

				K. Basso, U. Klein, H. Niu, G. A. Stolovitzky, Y. Tu, A. Califano, G. Cattoretti, and R. Dalla-Favera Tracking CD40 signaling during germinal center development Blood, December 15, 2004; 104(13): 4088 - 4096. [Abstract] [Full Text] [PDF]

				S. Manoj, P. J. Griebel, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Targeting with Bovine CD154 Enhances Humoral Immune Responses Induced by a DNA Vaccine in Sheep J. Immunol., January 15, 2003; 170(2): 989 - 996. [Abstract] [Full Text] [PDF]

				N. Zhu, L. M. Ramirez, R. L. Lee, N. S. Magnuson, G. A. Bishop, and M. R. Gold CD40 Signaling in B Cells Regulates the Expression of the Pim-1 Kinase Via the NF-{kappa}B Pathway J. Immunol., January 15, 2002; 168(2): 744 - 754. [Abstract] [Full Text] [PDF]

				I. Hellström, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellström CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer PNAS, May 18, 2001; (2001) 21557498. [Abstract] [Full Text]

				R. R. Furman, Z. Asgary, J. O. Mascarenhas, H.-C. Liou2, and E. J. Schattner Modulation of NF-{kappa}B Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells J. Immunol., February 15, 2000; 164(4): 2200 - 2206. [Abstract] [Full Text] [PDF]

				E. J. Schattner, J. Mascarenhas, I. Reyfman, M. Koshy, C. Woo, S. M. Friedman, and M. K. Crow Chronic Lymphocytic Leukemia B Cells Can Express CD40 Ligand and Demonstrate T-Cell Type Costimulatory Capacity Blood, April 15, 1998; 91(8): 2689 - 2697. [Abstract] [Full Text] [PDF]

				T. J. Smith, G. D. Sempowski, C. S. Berenson, H. J. Cao, H.-S. Wang, and R. P. Phipps Human Thyroid Fibroblasts Exhibit a Distinctive Phenotype in Culture: Characteristic Ganglioside Profile and Functional CD40 Expression Endocrinology, December 1, 1997; 138(12): 5576 - 5588. [Abstract] [Full Text] [PDF]

				F. M. Uckun, H. N. Sather, P. S. Gaynon, D. C. Arthur, M. E. Trigg, D. G. Tubergen, J. Nachman, P. G. Steinherz, M. G. Sensel, and G. H. Reaman Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group Blood, July 1, 1997; 90(1): 28 - 35. [Abstract] [Full Text] [PDF]

				I. Hellstrom, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellstrom CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer PNAS, June 5, 2001; 98(12): 6783 - 6788. [Abstract] [Full Text] [PDF]